Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells

BACKGROUND: Gemcitabine is the standard first-line chemotherapy regimen for pancreatic cancer. However, its therapeutic value is substantially limited in pancreatic cancer patients due to occurrence of resistance towards gemcitabine. A strategy of combined chemo-regimens is widely employed in clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hehe, Zhang, Zhengle, Gao, Chenggang, Wu, Shihong, Duan, Qingke, Wu, Heshui, Wang, Chunyou, Shen, Qiang, Yin, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582499/
https://www.ncbi.nlm.nih.gov/pubmed/31244991
http://dx.doi.org/10.1186/s13578-019-0312-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582499/
https://www.ncbi.nlm.nih.gov/pubmed/31244991
http://dx.doi.org/10.1186/s13578-019-0312-0

Ejemplares similares